Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
About 40 years ago the lipidization of hydrophilic drugs was proposed to induce their brain targeting by transforming them into lipophilic prodrugs. Unfortunately, lipidization often transforms a hydrophilic neuroactive agent into an active efflux transporter (AET) substrate, with consequent rejection from the brain after permeation across the blood brain barrier (BBB). Currently, the prodrug approach has greatly evolved in comparison to lipidization. This review describes the evolution of the prodrug approach for brain targeting considering the design of prodrugs as active influx substrates or molecules able to inhibit or elude AETs. Moreover, the prodrug approach appears strategic in optimization of the encapsulation of neuroactive drugs in nanoparticulate systems that can be designed to induce their receptor-mediated transport (RMT) across the BBB by appropriate decorations on their surface. Nasal administration is described as a valuable alternative to obtain the brain targeting of drugs, evidencing that the prodrug approach can allow the optimization of micro or nanoparticulate nasal formulations of neuroactive agents in order to obtain this goal. Furthermore, nasal administration is also proposed for prodrugs characterized by peripheral instability but potentially able to induce their targeting inside cells of the brain.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399330 | PMC |
| http://dx.doi.org/10.3390/pharmaceutics13081144 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Model-based prediction of nanoparticle and dissolved form ratios using total concentration data: a case study of SNB-101.
Front Pharmacol
August 2025
AIMS BioScience, Co., Ltd., Seoul, Republic of Korea.
Introduction: Irinotecan (CPT-11), a topoisomerase I inhibitor, serves as a prodrug for SN-38, its active metabolite with significantly higher cytotoxic potency. Despite its clinical efficacy, irinotecan's therapeutic potential is limited by low fraction of conversion to SN-38, inefficient tumor targeting, and dose-limiting toxicities such as diarrhea and neutropenia. Nanoparticle-based formulations, such as SNB-101, offer a promising solution by encapsulating irinotecan and SN-38, enhancing solubility, improving drug delivery efficiency, and reducing systemic toxicity through tumor-specific accumulation via the enhanced permeability and retention (EPR) effect.
View Article and Find Full Text PDFLipid-conjugated nucleoside prodrugs for antiviral therapy.
Bioorg Chem
August 2025
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. Electronic address:
Nucleoside analogs have served as the cornerstone of antiviral therapy by acting as antimetabolites that disrupt viral DNA or RNA synthesis, thereby effectively inhibiting viral replication. Despite their clinical success, many nucleoside-based antivirals suffer from intrinsic limitations such as poor lipophilicity, low membrane permeability, and rapid metabolic degradation, all of which compromise oral bioavailability and therapeutic efficacy. To address these challenges, lipid conjugation has emerged as a promising prodrug strategy that enhances pharmacokinetic properties, improves cellular uptake, and enables targeted delivery.
View Article and Find Full Text PDFTherapeutic strategies in cystinosis: A focus on cysteamine and beyond.
Exp Mol Pathol
September 2025
Azienda Sanitaria Locale di Salerno, 84124 Salerno, Italy.
Cystinosis is a autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene, which encodes cystinosin, a cystine transporter. The defective function of cystinosin leads to cystine accumulation in the lysosome, resulting in progressive multi-organ damage. Cystinosis manifests early in life, with nephropathic cystinosis typically presenting in infancy with renal Fanconi syndrome, leading to chronic kidney disease and end-stage renal disease if untreated.
View Article and Find Full Text PDFAligning organ-specific toxicities with formulation strategies: a rational design approach to chemotherapy optimization.
Int J Pharm
September 2025
School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Guangzhou 510275, China; School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China. Electronic address:
Chemotherapy-induced toxicity remains a persistent challenge in oncology, where multi-organ injury continues to limit clinical outcomes despite decades of drug optimization and formulation innovation. Although mechanistic studies have elucidated key pathways of damage, current formulation strategies often overlook organ-specific pathophysiology, resulting in nonspecific mitigation approaches. This review fills a methodological gap by introducing a toxicity-informed framework that integrates organ-specific injury mechanisms with formulation design principles to support rational chemotherapy optimization.
View Article and Find Full Text PDFROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and enhanced immune checkpoint inhibitor therapy in bladder cancer.
Biomaterials
September 2025
Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, Hubei Research Center for Biomaterials and Medical Protective Materials, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology (HUST), Wuhan, 430074, China.
Bladder cancer remains a formidable challenge, especially for patients who fail to respond adequately to immune checkpoint inhibitors (ICIs). The suboptimal efficacy of current treatments underscores an urgent need for more effective immunomodulatory strategies. Here, we propose a ROS-responsive resiquimod (R848) prodrug (R-P) that improves drug delivery and reshapes the immunosuppressive tumor microenvironment.
View Article and Find Full Text PDF